Skip to main content

Clinical Trials Using Gonadotropin-releasing Hormone Analog

Review the clinical trials studying gonadotropin-releasing hormone analog on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 26-42 of 42

Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer
Status: Active
Location: Mayo Clinic in Arizona, Scottsdale, Arizona
Leuprolide and Goserelin for Ovarian Function Suppression in Pre- or Peri-menopausal Women with Breast Cancer, OFS Trial
Status: Active
Location: University of Michigan Rogel Cancer Center, Ann Arbor, Michigan
Risk Stratified De-escalated Hormone Therapy with Radiation Therapy for the Treatment of Prostate Cancer
Status: Active
Location: Mayo Clinic in Arizona, Scottsdale, Arizona
Focal Therapy Combined with Androgen Deprivation Therapy for the Treatment of Localized Intermediate Risk Prostate Cancer
Status: Active
Location: University of Chicago Comprehensive Cancer Center, Chicago, Illinois
PSA Response-Based Radiation Therapy and Androgen Deprivation Therapy after Surgery for the Treatment of Relapsed Localized Prostate Cancer, RANGER Study
Status: Active
Location: UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas
Anastrozole, Fulvestrant, and Abemaciclib for the Treatment of Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer
Status: Active
Location: UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California
Relugolix or Leuprolide for the Treatment of Cardiac Function in Patients with Prostate Cancer
Status: Active
Location: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
MR-Linac-Guided Stereotactic Body Radiation Therapy with Androgen Deprivation Therapy for the Treatment of Locally Recurrent Prostate Adenocarcinoma
Status: Active
Location: Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York
Enzalutamide and Talazoparib with Androgen Deprivation Therapy for the Treatment of Patients with Prostate Cancer that is Metastatic to the Lymph Nodes at Diagnosis
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Testosterone and ZEN-3694 followed by Enzalutamide and ZEN-3694 for the Treatment of Asymptomatic Patients with Metastatic Castration-Resistant Prostate Cancer, The COSMYC Trial
Status: Active
Location: Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland
Androgen Deprivation Therapy and SBRT versus SBRT Alone for the Treatment of Unfavorable Intermediate Risk Prostate Cancer
Status: Active
Location: Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York
M9241 in Combination With Docetaxel in Adults With Metastatic Castration Sensitive and Castration Resistant Prostate Cancer
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients with Metastatic Castration Resistant Prostate Cancer
Status: Active
Location: Roswell Park Cancer Institute, Buffalo, New York
Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study
Status: Enrolling by Invitation
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
Radiation Therapy Using MRI-Guided Dosing for Prostate Cancer to Preserve Quality of Life
Status: Temporarily Closed to Accrual
Location: University of Chicago Comprehensive Cancer Center, Chicago, Illinois
Ovarian Simulation and Tamoxifen or Letrozole in Fertility Preservation in Patients with Breast Cancer, TALES Study
Status: Active
Location: 2 locations
Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults with Cancer
Status: Active
Location: 184 locations